{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:05:17Z","timestamp":1790147117089,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["JP22K06699"],"award-info":[{"award-number":["JP22K06699"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the relationship between teicoplanin trough concentrations and loading doses and to identify the appropriate body-weight descriptor for loading doses across BMI categories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective study included adult patients whose teicoplanin trough concentrations had been measured. Cumulative loading doses and trough concentrations were compared among the underweight (BMI\u200a&amp;lt;\u200a18.5\u2005kg\/m2), normal-weight (BMI 18.5\u201324.9\u2005kg\/m2) and overweight\/obese (BMI\u200a\u2265\u200a25.0\u2005kg\/m2) groups. Trough concentrations at the guideline-recommended loading dose scaled to different body-weight descriptors were simulated using individual pharmacokinetic parameters to evaluate the target attainment rate (TAR) within the target range 15\u201330\u2005mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 206 patients were analysed, comprising 35 underweight, 131 normal-weight and 40 overweight\/obese patients. The overweight\/obese group received significantly lower loading doses than the other two groups. In contrast, Day 4 trough concentrations did not differ significantly between the underweight, normal-weight and overweight\/obese groups, with median concentrations of 23.2, 23.7 and 24.1\u2005mg\/L, respectively. Simulation analysis showed that total body weight (TBW)\u2013based dosing achieved a high TAR in the underweight and normal-weight groups (84% and 85%, respectively) and a lower TAR (71%) with a higher median of 27.2\u2005mg\/L in the overweight\/obese group. The body-weight descriptor yielding a higher TAR than TBW-based dosing in the overweight\/obese group varied by target range, with overlapping 95% CIs indicating no clear superiority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Simulation analysis suggests that TBW-based loading doses may lead to teicoplanin overexposure in overweight\/obese patients. Further studies are warranted to identify the appropriate body-weight descriptor for loading doses in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag329","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:52:53Z","timestamp":1789041173000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of teicoplanin concentrations for loading-dose optimization across BMI categories"],"prefix":"10.1093","volume":"81","author":[{"given":"Mitsutaka","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Infection Control and Prevention, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-1727","authenticated-orcid":false,"given":"Takaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, School of Pharmaceutical Sciences, Wakayama Medical University , Wakayama 640-8156 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Inada","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wakayama Medical University Hospital , Wakayama 641-8509 ,","place":["Japan"]},{"name":"Department of Clinical Pharmacology and Pharmacotherapy, School of Pharmaceutical Sciences, Wakayama Medical University , Wakayama 640-8156 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092302571545800_dkag329-B1","author":"Electronic Medicines Compendium"},{"key":"2026092302571545800_dkag329-B2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026092302571545800_dkag329-B3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026092302571545800_dkag329-B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jgar.2020.11.014","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model","volume":"24","author":"Watanabe","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026092302571545800_dkag329-B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/CPAA.S96143","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"8","author":"Matsumoto","year":"2016","journal-title":"Clin Pharmacol"},{"key":"2026092302571545800_dkag329-B6","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Martin","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026092302571545800_dkag329-B7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01719-23","article-title":"Updated antimicrobial dosing recommendations for obese patients","volume":"68","author":"Castro-Balado","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092302571545800_dkag329-B8","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S1473-3099(25)00155-0","article-title":"The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments","volume":"25","author":"Martson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026092302571545800_dkag329-B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/ehjcvp\/pvae064","article-title":"Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology working group on cardiovascular pharmacotherapy and the European Society of Cardiology working group on thrombosis","volume":"10","author":"Gigante","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026092302571545800_dkag329-B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-023-01324-5","article-title":"How to dose vancomycin in overweight and obese patients with varying renal (dys)function in the novel era of AUC 400\u2013600 mg.h\/L-targeted dosing","volume":"63","author":"Zhang","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026092302571545800_dkag329-B11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026092302571545800_dkag329-B12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.2367","article-title":"Vancomycin pharmacokinetics in obese patients with sepsis or septic shock","volume":"40","author":"Masich","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2026092302571545800_dkag329-B13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jiac.2019.04.017","article-title":"Evaluation for optimal dosing of vancomycin in patients with different physical types","volume":"25","author":"Hashimoto","year":"2019","journal-title":"J Infect Chemother"},{"key":"2026092302571545800_dkag329-B14","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/jac\/dky310","article-title":"Dosing vancomycin in the super obese: less is more","volume":"73","author":"Crass","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026092302571545800_dkag329-B15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the Infectious Diseases Society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2026092302571545800_dkag329-B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026092302571545800_dkag329-B17","author":"SEKISUI MEDICAL CO., LTD"},{"key":"2026092302571545800_dkag329-B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan","volume":"71","author":"Ogawa","year":"2024","journal-title":"Endocr J"},{"key":"2026092302571545800_dkag329-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11250\/chemotherapy1995.54.1","article-title":"Population pharmacokinetics of teicoplanin in adult patients","volume":"54","author":"Nakayama","year":"2006","journal-title":"Jpn J Chemother"},{"key":"2026092302571545800_dkag329-B20","doi-asserted-by":"publisher","first-page":"674.e7","DOI":"10.1016\/j.cmi.2017.02.032","article-title":"Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic\/pharmacodynamic targets in adult patients with haematological malignancy","volume":"23","author":"Byrne","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026092302571545800_dkag329-B21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026092302571545800_dkag329-B22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijantimicag.2015.05.019","article-title":"Teicoplanin use in adult patients with haematological malignancy: exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity","volume":"46","author":"Byrne","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2026092302571545800_dkag329-B23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","article-title":"High-dose regimen to achieve novel target trough concentration in teicoplanin","volume":"20","author":"Ueda","year":"2014","journal-title":"J Infect Chemother"},{"key":"2026092302571545800_dkag329-B24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/ftd.0000000000000906","article-title":"Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies","volume":"43","author":"Sako","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2026092302571545800_dkag329-B25","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1093\/jac\/dkx242","article-title":"Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen","volume":"72","author":"Cazaubon","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026092302571545800_dkag329-B26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkx473","article-title":"Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy","volume":"73","author":"Byrne","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"2026092302571545800_dkag329-B27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1120009x.2000.11782313","article-title":"Comparative pharmacokinetics of teicoplanin and vancomycin","volume":"12","author":"Harding","year":"2000","journal-title":"J Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag329\/71332378\/dkag329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag329\/71332378\/dkag329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:57:22Z","timestamp":1790146642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag329\/8831030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag329","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dkag329"}}